Amgen announced that as part of the company's commitment to improve patient affordability for an innovative biologic medicine for people with high cholesterol who are at risk for heart attacks and ...

THOUSAND OAKS, Calif., Jan. 7, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that as part of the Company's commitment to improve patient affordability for an innovative biologic medicine ...

Repatha works by blocking a specific enzyme in your liver to help your body remove cholesterol more effectively. It is not an immunosuppressant drug, so it doesn’t work by suppressing the immune ...

Amgen continues to move toward completing its promise of shifting patients to a cheaper cost of its blockbuster anti-cholesterol drug Repatha, a PCSK9 (proprotein convertase subtilisin kexin type 9) ...

The Repatha Pushtronix System will be discontinued as of June 30, 2024. Amgen has announced that the Repatha (evolocumab) Pushtronix ® System (single-dose on-body infusor with prefilled cartridge) ...

The FDA approved Amgen’s AMGN new cholesterol-lowering medication, Repatha (evolocumab), making it the second PCSK9 inhibitor to gain approval in the U.S. this year. Repatha’s approval comes a month ...

THOUSAND OAKS, Calif., Amgen today announced the submission of an application to the U.S. Food and Drug Administration (FDA) seeking approval of a single-dosing option for the monthly administration ...

Credit: Amgen. The Repatha Pushtronix System will be discontinued as of June 30, 2024. The Repatha Pushtronix System will be discontinued as of June 30, 2024. Amgen has announced that the Repatha ...

The US Food and Drug Administration (FDA) has approved Amgen's cholesterol-lowering medication, Repatha (evolocumab) injection, a human monoclonal antibody that inhibits proprotein convertase ...